Drug intelligence / Profile preview

IMT-105-A01

Development stage: Preclinical
Lead developer: IMMUSE
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

IMT-105-A01 is a preclinical **antibody-drug conjugate** being developed by IMMUSE for **solid cancers**. It is described by the company as an ADC candidate derived from the IMT-105 new chemical entity platform and uses a **novel payload-linker technology** intended to target both **tumor cells** and **immune cells within the tumor microenvironment**. The specific molecular target and payload structure have not been publicly disclosed, but the program appears positioned within IMMUSE's tumor microenvironment-focused immuno-oncology pipeline.

Other names: IMT-105-A01-IMMUSE-ADC-Solid CancerIMT105-A01-IMMUSE-ADC-Solid CancerIMT 105-A01-IMMUSE-ADC-Solid Cancer

Beyond the preview

Go deeper on IMT-105-A01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-105-A01.

Explore the full profile